绥美凯怎么用？

It is an innovative AIDS treatment drug by ViiV Healthcare, a joint venture company of GlaxoSmithKline (GSK). It is currently the only three-in-one compound drug containing dolutegravir (DTG). It is clinically suitable for the treatment of adults and adolescents over 12 years old (with a weight of at least 40 kg) infected with human immunodeficiency virus (HIV). HIV-infected patients, regardless of race, should be screened for the HLA-B5701 allele before starting treatment with abacavir-containing products. If the patient is known to carry the HLA-B5701 allele, he should not take products containing abacavir.

Dolutegravir tablets are a compound preparation. Each tablet contains dolutegravir sodium (calculated as dolutegravir) 50 mg, abacavir sulfate (calculated as abacavir) 600 mg and lamivudine 300 mg. It is suitable for the treatment of adults and adolescents over 12 years old (with a weight of at least 40kg) infected with human immunodeficiency virus (HIV). Among them, dolutegravir can inhibit HIV integrase by binding to the active site of integrase and blocking the strand transfer step of reverse transcription deoxyribonucleic acid (DNA) integration (a key step in the HIV replication cycle).

Dolutegravir is a fixed-dose tablet and should not be used in patients who require dose adjustments. If one of the active ingredients needs to be discontinued or a dose adjustment is required, separate formulations of dolutegravir, abacavir, or lamivudine may be used. In these cases, physicians should refer to the respective product information for these medicines.

Miss a dose

If the patient misses a dose of Suimei Kai and there are more than 4 hours before the next dose, Sui Meikai should be taken as soon as possible. If the next dose is less than 4 hours away, patients should not take the missed dose and simply resume their usual dosing schedule.

elderly patients

There are limited data on the use of dolutegravir, abacavir, and lamivudine in patients aged ≥65 years, and there is no evidence that older patients require different doses than younger adults. Taking into account age-related changes, such as decreased renal function and changes in hematological parameters, special caution is recommended when administering the drug in this age group.

kidney damage

Patients whose creatinine clearance is less than 50 mL/min are not recommended to take doptabalamid tablets.

liver damage

Abacavir is primarily metabolized by the liver. There are no clinical data in patients with moderate or severe hepatic impairment, therefore, use of Trimax is not recommended unless deemed necessary. For patients with mild hepatic impairment (Child-Pugh score 5-6), close monitoring is required, including monitoring of abacavir plasma levels if feasible.

children crowd

The safety and effectiveness of Suimeikan in children under 12 years of age have not been established. No data yet.

Dosing method

Oral

Can be taken with or without food.